Dana Goldman and Darius Lakdawalla are evaluating affordable ways to address the rising number of Alzheimer’s disease and related dementias patients, including developing novel reimbursement frameworks, to ensure these patients have access when an innovative treatment becomes available.
Alzheimer’s research has been associated with many more downs than ups, but with Biogen’s surprising decision to file for market authorization of aducanumab, the next major challenge is for national healthcare systems to get ready.
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
Insufficient understanding of the completeness of dementia diagnosis and for whom in Medicare claims data limits their use. This study analyzes prevalence and incidence of dementia in survey and claims data to understand differences.